PD1/PD-L1 Axis Blockers in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis of Efficacy...

Area of Science:

• Oncology
• Immunotherapy
• Clinical Trials

Background:

• Head and neck squamous cell carcinoma (HNSCC) is a prevalent cancer.
• Standard therapies for HNSCC have limitations in efficacy and safety.
• Anti-PD1/PD-L1 inhibitors (APIs) represent a novel class of immunotherapies.

Purpose of the Study:

• To systematically review the safety and efficacy of anti-PD1/PD-L1 inhibitor (API) therapies in head and neck squamous cell carcinoma (HNSCC).
• To analyze the impact of APIs on overall survival (OS), duration of response (DOR), and adverse events in HNSCC patients.

Main Methods:

• Systematic review of randomized controlled trials (RCTs) identified through comprehensive literature searches (PubMed, Cochrane, ClinicalTrials.gov) up to May 31, 2024.
• Inclusion of nine RCTs involving 3933 participants treated with APIs for HNSCC.
• Data analysis using Review Manager (RevMan) with assessment of risk of bias and methodological quality.

Main Results:

• API treatment significantly improved overall survival (OS) in HNSCC patients compared to standard therapy (HR=0.85, P=0.004).
• Substantial OS improvement was observed even in patients with PD-L1 expression ≥1% treated with APIs.
• Duration of response (DOR) was notably enhanced with API therapy (HR=0.31, P <0.00001), alongside a reduced incidence of treatment-related adverse events, including Grade 3/4 effects.

Conclusions:

• Anti-PD1/PD-L1 inhibitors (APIs) offer a significant survival benefit and improved duration of response in HNSCC management.
• APIs present a favorable safety profile compared to traditional chemotherapy and combination immunotherapy.
• APIs represent a promising alternative therapeutic strategy for HNSCC, potentially improving patient outcomes and paving the way for novel treatment approaches.